AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
enGene Therapeutics Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG01J1GCYX6
1.56▼ 0.02 (-1.27%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.58
Day's Range
1.54 – 1.58
52-Week Range
1.40 – 12.25
Volume
730.2K
Avg Volume
799.3K
Share Statistics
Shares Outstanding
Employees
82
Exchange
XNAS
Listed
2023-11-01
Share count as of September 2, 2026

enGene Therapeutics Inc. Common Stock (ENGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about enGene Therapeutics Inc. Common Stock (ENGN)
What is enGene Therapeutics Inc. Common Stock's Market Cap?
enGene Therapeutics Inc. Common Stock's Market Cap is $104.5M, based on as-reported figures from SEC (XBRL) filings.
What is enGene Therapeutics Inc. Common Stock's Enterprise Value?
enGene Therapeutics Inc. Common Stock's Enterprise Value is $63.5M, based on as-reported figures from SEC (XBRL) filings.
What is enGene Therapeutics Inc. Common Stock's EV / EBITDA?
enGene Therapeutics Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is enGene Therapeutics Inc. Common Stock's Net Income (TTM)?
enGene Therapeutics Inc. Common Stock's Net Income (TTM) is -$130.4M, based on as-reported figures from SEC (XBRL) filings.
What is enGene Therapeutics Inc. Common Stock's EBITDA?
enGene Therapeutics Inc. Common Stock's EBITDA is -$135.9M, based on as-reported figures from SEC (XBRL) filings.
What is enGene Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
enGene Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -1.95, based on as-reported figures from SEC (XBRL) filings.
What is enGene Therapeutics Inc. Common Stock's Net Debt?
enGene Therapeutics Inc. Common Stock's Net Debt is -$41.0M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ENGNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJul 31, 2026Apr 30, 2026Jan 31, 2026Oct 31, 2025Jul 31, 2025Apr 30, 2025Jan 31, 2025Oct 31, 2024Jul 31, 2024Apr 30, 2024Jan 31, 2024Oct 31, 2023Jul 31, 2023Apr 30, 2023Jan 31, 2023
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other expenses (income), net:
Interest income
Interest expense
Loss on extinguishment of debt—
Other expenses, net—
Total other income, net
Net loss before income taxes
Net loss
Net loss per share of common shares, basic
Net loss per share of common shares, diluted